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Biomarkers of progression in diabetic
nephropathy: The past, present and future
More than 380 million people are currently suffering from dia-
betes. The International Diabetes Federation estimated that this
would rise to 592 million within a generation. Despite this
relentless increase in the prevalence of type 2 diabetes world-
wide, with the advent of potent statins, there has been a grad-
ual decline in mortality from macrovascular complications,
such as stroke and coronary heart disease. However, this is not
the situation in diabetic nephropathy, which remains a leading
cause of end-stage renal disease (ESRD) globally, with its inci-
dence being still on a rising trend. Notably, once nephropathy
develops, approximately 20–40% of patients inevitably progress
to ESRD. Therefore, we need biomarkers that would enable
early risk stratification in diabetic nephropathy (Figure 1), so
that those at higher risk of progression to ESRD are identified
at early stages of nephropathy development. Long-term follow
up of interventional studies, such as STENO-2, have clearly
shown that, even at the stage of microalbuminuria, intensive
multifactorial management targeting blood pressure (particu-
larly with blockade of the renin–angiotensin system), glucose,
cholesterol and lifestyle issues could reduce the progression to
ESRD as well as the associated cardiovascular mortality. The
availability of sensitive and well-validated biomarkers for
nephropathy progression would allow targeted intensive man-
agement to be provided to those who would derive the most
cost-effective benefits from such intervention.
In the past, persistent microalbuminuria was the most studied
biomarker in diabetic nephropathy. Both the presence and the
incremental changes in microalbuminuria had been shown to
correlate with the development and progression of chronic
kidney disease in type 1 and type 2 diabetes. Furthermore,
microalbuminuria was also shown to be a risk factor for the
development of macrovascular complications in diabetic patients.
These were all good reasons for incorporating the measurement
of urinary albumin excretion into our clinical practice until the
recent decade, when microalbuminuria was challenged for its
high variability, low sensitivity and specificity in predicting kid-
ney disease progression in diabetic nephropathy. This change in
paradigm was supported by the observation that spontaneous
remission of microalbuminuria could occur in more than half of
diabetic patients. Furthermore, 20% of type 2 diabetic patients
had their glomerular filtration rate (GFR) decline to ≤60 mL/
min/1.73 m2 before or even without passing the stage of microal-
buminuria. Therefore, the progression of diabetic nephropathy, if
defined as a deterioration in chronic kidney disease (CKD) stag-
ing or a decline in GFR, is not necessarily in parallel with the pro-
gression in urinary albumin excretion. Hence, in a proportion of
diabetic patients, microalbuminuria might not be sufficient as a
marker to identify or stratify those at risk of kidney disease pro-
gression or ESRD, especially if we aim at intervening at an early
stage of diabetic nephropathy.
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Figure 1 | Emerging biomarkers of diabetic nephropathy in relation to disease pathogenesis. FABPs, fatty acid binding proteins; FGF, fibroblast
growth factor; GFR, glomerular filtration rate; PADF, pigment epithelium-derived factor; TNF, tumor necrosis factor.
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This has led to active research on new prognostic biomarkers
for progressive diabetic nephropathy in recent years. Of the
emerging candidate biomarkers, serum cystatin C, fibroblast
growth factor 23 (FGF23) and soluble tumor necrosis factor
(TNF) receptors have provided the most promising data. Serum
cystatin C is produced by all nucleated cells, freely filtered by
the glomeruli and completely metabolized by the proximal
renal tubules. An observational study by Krolewski et al.1
showed that the measurement of serum cystatin C improved
the risk prediction of nephropathy progression to ESRD in
type 2 diabetic patients. They recruited more than 1,000 dia-
betic patients from three Caucasian cohorts, with CKD
stages 1–3 at baseline, and followed them up for 8–10 years.
These subjects had baseline estimated GFR (eGFR) measured
by both serum creatinine and serum cystatin C. Subjects given
a higher baseline CKD stage by cystatin C-based eGFR than by
creatinine-based eGFR had a significantly higher risk of pro-
gression to ESRD compared with those with concordant stag-
ing, suggesting a superior risk prediction by cystatin C-based
eGFR. Markers of inflammation are also potential candidates
for the prediction of progressive kidney disease in diabetes, as
inflammation is clearly one of the key players in the pathogene-
sis of diabetic nephropathy (Figure 1). Both FGF23, an endo-
crine hormone related to phosphate homeostasis and
vitamin D activation, and circulating TNF receptors (1 and 2),
had been shown to predict renal outcome in type 2 diabetes.
Niewczas et al.2 showed that raised baseline levels of TNF
receptors 1 and 2 predicted the progression to ESRD in more
than 400 type 2 diabetic patients after 12 years of follow up,
even after adjustment for urinary albumin excretion. Further-
more, it was shown in another study that the predictive effect
of FGF23 on the risk of progression in diabetic nephropathy
was dependent on the TNF receptor 1, likely because the
downregulation of Klotho by TNF-a leads to FGF23 resistance
and hence a compensatory increase in FGF23 expression. These
suggested the superiority of using serum TNF receptor 1 over
conventional biomarkers, such as microalbuminuria, as it could
predict the progression to ESRD, a hard renal end-point, irre-
spective of the presence or absence of albuminuria. This is cer-
tainly relevant to the subset of diabetic patients discussed
above, who suffered from GFR decline without passing through
the stage of microalbuminuria. Recently, fatty acid binding pro-
teins, a group of diverse proteins involved in lipid homeostasis,
have also been reported as potential biomarkers for diabetic
nephropathy. Elevated urinary levels of liver-fatty acid binding
protein (L-FABP) were detected in diabetic patients even before
the onset of microalbuminuria. As diabetic nephropathy is
characterized by the renal accumulation of activated macro-
phages, it is perhaps not surprising that serum levels of adipo-
cyte-fatty acid binding protein (A-FABP), which is highly
expressed in macrophages, are independently associated with
nephropathy staging in type 2 diabetes3. Data presented at the
2014 Diabetes Congress of the International Diabetes Federa-
tion – West Pacific Region suggest that serum A-FABP might
also independently predict early eGFR decline in type 2 diabetic
patients.
Another two potential novel biomarkers of progression in
diabetic nephropathy have recently been identified: pigment
epithelium-derived factor (PEDF) and FGF21 (Figure 1)4,5.
PEDF is a secreted circulating glycoprotein with anti-oxidative,
anti-inflammatory and anti-angiogenic properties, whereas
FGF21 is a hormone predominantly secreted from the liver and
possess multiple metabolic regulatory properties. In a cohort
involving more than 1,000 Chinese type 2 diabetic patients with
baseline eGFR ≥60 mL/min/1.73 m2, both baseline circulating
PEDF and FGF21 levels were shown to be independent predic-
tors of the decline in renal function. In addition, in subgroups
of diabetic patients with relatively well-preserved kidney func-
tion, with an eGFR ≥60 mL/min/1.73 m2 and normoalbuminu-
ria, baseline serum PEDF and FGF21 levels were independently
associated with the progression to micro- or albuminuria and
eGFR decline respectively, even after adjusted for baseline eGFR
levels. Further evaluation in other cohorts is certainly warranted
to confirm these exciting findings. It is interesting to note that
PEDF is expressed in the kidney, and renoprotective as well as
anti-inflammatory effects of PEDF have been shown in diabetic
rats with microalbuminuria. In contrast, impaired FGF21 sig-
naling in the kidney has been found in db/db mice, a rodent
model of type 2 diabetes. In the adipose tissue of obese mice,
such impaired signaling or FGF21 resistance has been attrib-
uted to local inflammation and TNF-a induced downregulation
of b-Klotho, the obligatory coreceptor protein for FGF21 signal-
ing. Increased local FGF21 expression has also been found in
response to drug-induced renal and liver injury, and exogenous
FGF21 results in decreased renal apoptosis, suppressed diabe-
tes-induced renal inflammation, oxidative stress and fibrosis in
animal models. Taken together, the elevation in both serum
PEDF and FGF21 levels might simply reflect compensatory
responses, and reflect on the severity of the underlying renal
inflammation and injury in type 2 diabetes, which would con-
tribute to the development and progression of diabetic
nephropathy. (Figure 1) In addition, not only are serum PEDF
and FGF21 potential biomarkers for identifying diabetic
patients at risk of nephropathy progression, especially at early
stages of diabetic nephropathy, FGF21 could also serve as a
novel therapeutic target in the treatment of diabetic nephropa-
thy. Beneficial effects of an FGF21 analog on metabolic param-
eters including hyperlipidemia, bodyweight and
hyperinsulinemia have recently been shown in type 2 diabetic
patients, despite the presence of FGF21 resistance.
To conclude, there is clearly a need for novel biomarkers
with high sensitivity and specificity for predicting the progres-
sion of diabetic nephropathy. The identification of good bio-
markers, in addition to providing useful tools for early renal
risk stratification, could also bring new insights into the patho-
genesis of diabetic nephropathy, and open up new therapeutic
options for preventing nephropathy progression. With advances
in proteomics, genomics and translational research, it is antici-
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pated that more biomarkers will continue to be discovered. It
will certainly be a long road from the discovery of a new bio-
marker to its clinical application as a routine assay or as a ther-
apeutic agent for patient management. Universal validation and
standardization of each and every biomarker involve significant
time and cost. Even more demanding efforts and costs are
entailed in drug development and clinical trials. Nevertheless,
all scientists working in this field of biomarker research,
whether in the past, present or future, deserve to be applauded
for their unswerving efforts to prevent the development and
progression of diabetic nephropathy, and bring new hope to
people with diabetes.
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